KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Discontinued Operations (2015 - 2016)

Abbott Laboratories recorded quarterly Cash from Discontinued Operations of 25000000.0 in Q1 2016, up 733.33% quarter-over-quarter from 3000000.0 in Q4 2015, and down 99.11% year-over-year from 2821000000.0 in Q2 2015.

Abbott Laboratories' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 25000000.0 for Q1 2016.

  • In Q1 2016, Cash from Discontinued Operations fell 99.11% year-over-year to 25000000.0; the TTM figure through Dec 2016 stood at 25000000.0 (down 99.12% YoY), while the FY2016 annual figure was 25000000.0, down 99.12% from the prior year.
  • Cash from Discontinued Operations came in at 25000000.0 for Q1 2016 at Abbott Laboratories, up from 3000000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 2821000000.0 in Q1 2015 to a low of 1000000.0 in Q2 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2016 25.00 Mn
Mar 31, 2016 25.00 Mn
Dec 31, 2015 3.00 Mn
Dec 31, 2015 3.00 Mn
Sep 30, 2015 17.00 Mn
Sep 30, 2015 17.00 Mn
Jun 30, 2015 -1.00 Mn
Jun 30, 2015 -1.00 Mn
Mar 31, 2015 2.82 Bn
Mar 31, 2015 2.82 Bn